Ask AI
Oral Therapies in HR Positive HER2 Negative Breast Cancer

CE

Targeted Therapy Advances in HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 31, 2026

Expiration: January 30, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Jordan Hill, PharmD, BCOP, and Danielle Roman, PharmD, BCOP​, discuss the evolving treatment landscape for hormone receptor (HR)–positive/HER2-negative breast cancer, reviewing key clinical trial data, biomarker-driven treatment selection, and practical considerations for integrating targeted therapies into early-stage and metastatic disease management.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary. 

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with breast cancer do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

In my current practice, I am confident in applying the latest efficacy data for oral targeted therapies to clinical practice to individualize the management of patients with HR-positive/HER2-negative breast cancer.

Based on data from the phase III CAPItello-291 trial, capivasertib plus fulvestrant shows increased progression-free survival (PFS) benefit for patients with HR-positive/HER2-negative metastatic breast cancer (MBC) that has progressed on ≥1 endocrine-based regimen in the metastatic setting and which of the following molecular alterations?